Studies Confirm Benefit of Plasma Genotyping to Predict Treatment Benefit in Patients with Non-Small-Cell Lung Cancer
The benefit of plasma genotyping to predict treatment benefit in patients with non-small-cell lung cancer (NSCLC) is confirmed in three studies presented today at the European Lung Cancer Conference (ELCC) 2016 in Geneva, Switzerland